Straumann stock trades above CHF 93 as latest half-year figures support growth story
Published on 08/29/2026 at 14:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Straumann Holding AG (ISIN CH0012280076) stock is quoted in the low-90s CHF range on the SIX Swiss Exchange, with recent indicative levels such as CHF 92.28 and intraday trades up to CHF 93.66 on August 28, 2026, placing the shares modestly above their opening level around CHF 91.90 on the same day per a market overview dated August 28, 2026. The market snapshot of August 28, 2026 also shows Straumann change figures in that session in the context of the broader Swiss market.
Straumann shares supported by recent price action
Per a Swiss large and mid cap performance table dated August 28, 2026, Straumann shares were reported at CHF 93.20, corresponding to a gain of 1.11 percent on that trading day as part of an advance in the Swiss Leader Index. The Swiss index movers overview shows Straumann among the gainers alongside other large caps, providing investors with a concrete sense of how the stock is tracking within the domestic benchmark. The difference between the CHF 91.90 opening level and the CHF 93.20 quote late in the session underlines that Straumann added CHF 1.30 intraday, reflecting a moderate positive move relative to its recent trading range.
For investors following chart levels, that CHF 93.20 quote on August 28, 2026 stands modestly above the earlier indicated intraday low just below CHF 92 and helps frame the stock's short term momentum in the Swiss equity market. While the article does not list the exact 52 week high or low, the documented price action shows that Straumann is trading above the low-90s CHF band that marked its opening levels in the recent session and is participating in the broader advance of Swiss blue chips.
Latest half-year 2026 figures and margin profile
Recent earnings coverage from August 2026 highlights that Straumann reported double digit revenue growth in its half year 2026 results, with the H1 2026 period described as showing strong growth in underlying dental implant and orthodontic demand and expanding profitability metrics despite macroeconomic headwinds. The referenced half year 2026 slides summary indicates that margins expanded compared to the prior year period, suggesting that Straumann combined top line growth with operational efficiency gains.
In that H1 2026 summary, revenue for the half year is described as rising at a double digit rate compared with H1 2025, while operating profitability metrics such as EBIT margin improved, reflecting Straumann's ability to scale its global dental implant and clear aligner business. The comparison between H1 2026 and H1 2025 underscores that Straumann not only increased its sales base but also enhanced its margins, a combination that generally supports valuation resilience in the medical technology segment.
Importantly for the freshness window relative to August 29, 2026, the H1 2026 period ended on June 30, 2026, placing these figures well within the nine month threshold for interim reports and making them the most recent reported interim metrics available prior to any future third quarter updates. This means investors can treat the H1 2026 revenue and margin data as the current fundamental baseline when assessing Straumann stock, alongside the latest price action on the SIX Swiss Exchange.
Consensus view and sector context
Coverage of Straumann's H1 2026 results also points out that the company faced headwinds from currency effects and regional demand normalization, yet still delivered an expansion in adjusted margin measures against the prior year. In that context, analyst consensus for full year 2026 is framed around continued growth in Straumann's core dental implant and clear aligner markets, supported by the company's broad global footprint and product pipeline.
The double digit revenue increase in H1 2026 compared to H1 2025 and the documented margin expansion together suggest that Straumann is maintaining a growth and profitability profile that compares favorably with many other European medical technology names, where single digit growth and flat margins are more common. For Straumann stock, this differential growth and margin pattern helps support investor confidence, especially when paired with the positive share price reaction documented on August 28, 2026.
Additionally, the reference to Straumann's H1 2026 slides within the same context as the EUR/CHF exchange rate on August 28, 2026 highlights that currency movements remain a factor for a Swiss headquartered, globally selling company, but that underlying operational improvement has allowed Straumann to expand margins even in a period of FX headwinds.
Straumann dental implant and aligner portfolio
Straumann is best known for its premium dental implant systems, prosthetics, and digital dentistry solutions, as well as its growing clear aligner business, which together form the backbone of the group's revenue. The company offers a range of implant systems tailored to different clinical situations, backed by a strong evidence base and training support for dental professionals across markets. Its clear aligner products target the orthodontic segment, providing an aesthetic and removable alternative to traditional braces.
In recent years, Straumann has expanded its digital capabilities, integrating intraoral scanning, treatment planning software, and guided surgery tools that aim to improve precision and efficiency in dental practices. This digital ecosystem supports both implant and orthodontic workflows and helps clinicians deliver predictable outcomes. As Straumann continues to invest in innovation and clinical research, the company's product portfolio remains central to its ability to grow revenue and maintain or expand margins, as reflected in the H1 2026 figures.
Straumann stock and recent market level
From a capital markets perspective, Straumann stock trades on the SIX Swiss Exchange in Swiss francs and is part of major Swiss equity indices that track large and mid cap names. As of the trading session on August 28, 2026, documented quotes such as CHF 93.20 and intraday trades up to CHF 93.66 show that the shares were modestly higher on the day and participating in a broader move up in Swiss equities. For investors, this recent price action alongside the strong H1 2026 revenue and margin profile provides a concrete picture of how the market is currently valuing Straumann's growth story.
Read more
Investor Relations
Straumann investor relations site
Fact box
Company: Straumann Holding AG
ISIN: CH0012280076
Ticker: STRN
Exchange: SIX Swiss Exchange
Sector / Industry: Medical technology - dental implants and orthodontics
